ENXTPA:ABVXBiotechs
A Look At Abivax Société Anonyme’s Valuation After New Obefazimod Data At ECCO 2026
Why obefazimod data at ECCO 2026 matters for ABIVAX Société Anonyme (ENXTPA:ABVX)
ABIVAX Société Anonyme (ENXTPA:ABVX) drew fresh attention after releasing new preclinical and Phase 3 data for its lead drug obefazimod at ECCO 2026, focused on inflammatory bowel disease.
The company highlighted anti fibrotic signals in Crohn’s disease models, rapid symptomatic relief in ulcerative colitis, and safety data where serious treatment emergent adverse events and discontinuations were broadly...